Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Insights - The report highlights the acceleration of service consumption policies, with the State Council issuing a plan to enhance service consumption across various sectors, including transportation, tourism, and home services. This is expected to significantly boost the industry's outlook in 2026 [4] - The social service sector has shown strong relative performance, with a 1-month increase of 4.2%, a 3-month increase of 4.9%, and a 12-month increase of 17.5%, outperforming the CSI 300 index [3] Summary by Relevant Sections Service Consumption Policy - The government has introduced a comprehensive plan to enhance service consumption, focusing on expanding supply, innovating scenarios, and providing financial support. Key initiatives include promoting railway tourism, upgrading cruise and yacht products, and enhancing home service professionalization [4] Human Resources Service Sector - The report mentions that Core International expects a net profit of 267 million to 334 million yuan for 2025, representing a year-on-year growth of 30% to 62.5%. The company is leveraging technological innovation and industry integration to meet talent demands [5] Scenic Area Sector - Three Gorges Tourism anticipates a net profit of 56 million to 72 million yuan for 2025, reflecting a decline of 38.77% to 52.38% year-on-year, primarily due to tax payments and asset impairment losses [6][7] Investment Recommendations - The report suggests focusing on the human resources service sector, particularly companies like Core International and Beijing Renli. It also highlights opportunities in the duty-free sector, scenic areas, medical aesthetics, catering, tea drinks, and hotels, with specific companies recommended for investment [8]

Group 1 - The Hainan Province Danzhou Market Supervision Bureau and the Health Commission have launched a special inspection action focusing on the medical beauty market, particularly targeting various beauty institutions such as beauty salons and SPA centers [1] - A joint inspection team was formed to conduct surprise checks on 15 beauty establishments in the Nada Town area, assessing their qualifications, business projects, and the legality of their use of botulinum toxin and other prescription-required drugs [1] - During the inspections, enforcement personnel educated the responsible parties about relevant laws and regulations, emphasizing the legal responsibilities and safety requirements for using botulinum products [1] Group 2 - The market supervision department has reminded consumers that botulinum toxin injections are medical procedures that must be performed in licensed medical institutions by qualified physicians [2] - Consumers are advised to verify the qualifications of institutions and personnel before receiving services, ensuring the legality of the products used and retaining relevant evidence such as medical records and receipts [2] - The Danzhou Market Supervision Bureau plans to maintain a high-pressure regulatory stance, increasing daily supervision and special inspection efforts while enhancing collaboration with health and public security departments to purify the medical beauty market environment [2]

Core Viewpoint - Huaxi Biological Technology Co., Ltd. is expected to see significant profit growth in 2025, driven by operational efficiency improvements and strategic adjustments, despite a recent decline in stock price from a peak of 313 yuan to around 50 yuan per share [1][9]. Financial Performance - The company anticipates a net profit attributable to shareholders of 270 million to 320 million yuan for 2025, representing a year-on-year increase of 54.93% to 83.63% [3][11]. - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a growth rate of 55.68% to 102.29% [3][11]. - The low base from 2024, where the total profit was 213 million yuan and net profit was 174 million yuan, contributes to the substantial growth figures [3][11]. Business Strategy and Operations - The core driver of the expected profit growth is the steady improvement in the main business, focusing on "agile management and growth efficiency" [3][11]. - The company is optimizing its organizational structure, integrating overlapping functions, and upgrading operational models to shift from "scale expansion" to "quality growth" [4][12]. - Management expenses are expected to decrease by over 10% year-on-year, while sales expenses are projected to drop by more than 30% [4][12]. Research and Innovation - Huaxi Biological is enhancing its research capabilities in glycoscience and cell biology, focusing on cutting-edge studies related to extracellular matrix regulation and aging intervention [4][12]. - The company is leveraging AI technology to optimize business processes and improve operational efficiency across the supply chain and management [4][12]. Shareholder Activity - Recently, a long-term shareholder, Guoshou Chengda, reduced its stake by 2.00%, selling approximately 9.63 million shares for about 428 million yuan [5][13]. - Following the reduction, Guoshou Chengda's holdings decreased to 4.01%, exiting the top five shareholders [5][13]. Future Outlook - Analysts expect continued improvement in the company's operations in 2026, with stable growth in raw material business and positive trends in medical terminal business [6][13]. - The skin science innovation sector is entering a reform phase, focusing on structural adjustments [6][13].

Core Viewpoint - Huaxi Biological announced an expected net profit of 270 million to 320 million yuan for 2025, representing a year-on-year growth of 54.93% to 83.63% [1] - The growth is attributed to a systematic transformation rather than short-term scale expansion, focusing on "agile management, growth, and efficiency" [1][3] Financial Performance - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] - Management expenses are expected to decrease by over 10% year-on-year in 2025 [1] Operational Strategy - The company emphasizes professional development and optimizes its business structure and resource allocation, leading to a sales expense reduction of over 30% [2] - Cost and expense management has been refined to support profit growth [2] Innovation and Digital Transformation - Huaxi Biological focuses on scientific research as its core competitive advantage, particularly in glycoscience and cell biology [2] - The company is enhancing its industrialization capabilities in bioactive substances and regenerative materials through a synthetic biology research and development system [2] - Continuous digital transformation is improving operational efficiency across all business scenarios, including AI integration in various functions [2] Long-term Development - The 2025 performance growth reflects the company's commitment to high-quality development and core capability building [3] - The company aims to maintain its competitive advantage through technological innovation and a comprehensive industrial layout [3]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors, including gold and jewelry, offline retail, cosmetics, and medical aesthetics [6][49] Summary by Sections Retail and Social Services Market Review - For the week of January 26 to January 30, the retail and social services indices closed at 2435.34 points and 9283.84 points, respectively, with declines of 4.18% and 3.45% [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Industry Dynamics: HBN and Efficacy Skincare - HBN, established in 2019, is the largest domestic skincare brand in the efficacy segment, focusing on visible results and innovative product strategies [24][25] - The brand's core products, including the "A Retinol" series, have achieved significant sales milestones, with a strong emphasis on scientific validation and consumer trust [29][33] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuang and Chaohongji [6][49] - Offline retail companies adapting to market changes, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Domestic cosmetics brands that emphasize emotional value and safety, recommending brands like Maogeping and Proya [6][50] - Medical aesthetics firms with unique product lines, recommending Meilitiantian Medical Health and Aimeike [6][51]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and suggests focusing on high-quality companies in high-growth sectors [6][49] Summary by Sections Industry Performance Overview - The commercial retail and social services indices reported declines of 4.18% and 3.45% respectively during the week of January 26 to January 30, 2026, ranking 26th and 23rd among 31 primary industries [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Key Industry Developments - HBN, established in 2019, is recognized as the largest domestic skincare brand in the efficacy skincare segment, with a market share of 0.8% in the Chinese improvement skincare market as of 2024 [24][25] - HBN's revenue for the first three quarters of 2025 reached 1.51 billion yuan, a year-on-year increase of 10.2%, with high-efficacy skincare products accounting for 78.6% of total revenue [29] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopuhuangjin and Chaohongji [6][49] - Investment Theme 2: Highlighting retail companies that adapt to emotional value and intelligent trends, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Investment Theme 3: Emphasizing beauty and personal care brands that innovate with emotional value and safe ingredients, recommending brands like Maogeping and Pola [6][50] - Investment Theme 4: Targeting differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Aimeike and Meilitiantian [6][51]

Core Insights - Company is accelerating its scale operations by collaborating with 14 upstream suppliers and plans to open 35 new offline stores in the coming year, transitioning from an online medical beauty platform to a physical medical institution with a low-price model [1][6][7] Group 1: Strategic Partnerships - The establishment of the "Youth Selection Alliance" with 14 upstream suppliers aims to achieve mutual growth through price linkage, tiered supply, training collaboration, and product traceability [3] - This partnership indicates an improvement in the pricing issues that previously strained relationships with suppliers, allowing for a more stable collaboration [3][5] - Notable suppliers in this alliance include Allergan, Medimime, and others, which have previously raised concerns over pricing discrepancies with the company [3][4] Group 2: Pricing Strategy - The company has consistently aimed to lower the prices of its products, such as the "童颜针" (youthful needle), which saw significant price reductions over the years, making it more accessible to consumers [4][6] - The low-price strategy is seen as a way to attract new consumers, although the long-term sustainability of this approach will depend on product effectiveness and perceived value [4][5] Group 3: Operational Expansion - As of now, the company has established 50 stores across 16 cities, with plans to add at least 35 more stores by the end of 2026, aiming for a total of 500 doctors and 1000 nursing staff [7] - The company is entering a strategic transformation phase, focusing on improving operational gross margins while maintaining its scale advantage [7][8] Group 4: Financial Performance - The company reported a total revenue of 1.063 billion yuan for the first three quarters of 2025, a decrease of 3.17% year-on-year, with a loss of 133 million yuan [8][9] - The beauty treatment services segment has become the largest revenue source, contributing 427 million yuan, a significant increase of 385.05% year-on-year, accounting for 40.16% of total revenue [9] - The goal for 2026 includes achieving quarterly profitability while enhancing gross margins through a diverse product offering [8][9]

Core Viewpoint - The recent arbitration decision allows REGEN, a subsidiary of Aimeike, to sell AestheFill products in mainland China, but this is not a final ruling, and the ongoing dispute over distribution rights remains uncertain [2][8][20]. Group 1: Arbitration and Market Impact - Aimeike's subsidiary REGEN received a procedural decision from the Shenzhen International Arbitration Court, lifting a temporary measure that previously restricted its sales of AestheFill products in mainland China [2][8]. - Since the initial temporary measure was imposed on September 10, 2025, Aimeike's stock price has dropped nearly 30% [3]. - The arbitration dispute began after Aimeike acquired 85% of REGEN for $190 million in March 2025, leading to REGEN unilaterally terminating its exclusive distribution agreement with Dato Medical [6][8]. Group 2: Business Performance - Aimeike has faced a decline in revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues of 663 million, 636 million, and 566 million yuan, representing year-on-year declines of 17.90%, 25.11%, and 21.27% respectively [11]. - The decline in revenue is attributed to a weakened consumer confidence due to macroeconomic conditions and increased competition in the medical aesthetics industry [14][15]. - Aimeike's main revenue sources, solution and gel injection products, saw significant revenue drops, with total income from these products falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 [15][16]. Group 3: Future Outlook - The AestheFill product, despite its potential, is expected to contribute only around 300 million yuan in annual sales, which may not significantly offset the revenue decline from Aimeike's core products [17]. - The competitive landscape for botulinum toxin products is also challenging, with established players dominating the market, making it difficult for Aimeike to gain market share with newly approved products [18]. - Overall, Aimeike is likely to continue facing significant performance pressures into 2026, despite the short-term positive impact of the arbitration decision [19][20].

Core Viewpoint - The arbitration decision to lift the temporary sales restriction on AestheFill products by REGEN, a subsidiary of Aimeike, is seen as a short-term positive development, but the underlying dispute over distribution rights remains unresolved, indicating potential volatility in the company's stock performance [1][4][14]. Group 1: Arbitration and Sales Rights - REGEN received a decision from the Shenzhen International Arbitration Court on January 29, 2025, which lifted a temporary measure that prohibited the sale of AestheFill products in mainland China [1]. - The temporary measure was initially imposed following REGEN's unilateral termination of its exclusive distribution agreement with Dato Medical, which claimed that Dato had transferred its distribution rights to a related party, violating the agreement [3][4]. - The arbitration decision is procedural and not a final ruling, meaning the dispute over the legality of REGEN's termination of the distribution rights is still ongoing [4]. Group 2: Financial Performance - Aimeike has experienced a decline in both revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues reported at 663 million, 636 million, and 566 million yuan, reflecting year-on-year decreases of 17.90%, 25.11%, and 21.27% respectively [5][6]. - The company's core products, including solution and gel injection products, saw significant revenue drops, with total income from these categories falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 for solution products, and from 6.49 billion yuan to 4.93 billion yuan for gel products [9][10]. - The competitive landscape has intensified, with new entrants in the aesthetic medicine market impacting Aimeike's profit margins and market share [8][9]. Group 3: Future Outlook - The introduction of AestheFill is expected to provide some revenue support, but its annual sales of approximately 300 million yuan may not be sufficient to offset the significant revenue declines from Aimeike's core products [10][11]. - The company faces challenges in gaining market share for newly approved products, such as botulinum toxin, due to established competitors dominating the market [12][13]. - Overall, Aimeike is likely to continue facing substantial performance pressures into 2026, with the recent arbitration decision providing only a temporary boost [14].

Core Insights - The medical beauty market is experiencing a surge in demand as consumers prepare for the upcoming Spring Festival, with many opting for aesthetic treatments to enhance their appearance [1][3]. Group 1: Market Trends - There has been a significant increase in user visits to medical beauty services, with Meituan reporting over a 15% year-on-year growth and nearly a 10% week-on-week increase [3]. - The demand for aesthetic treatments is primarily focused on anti-aging, wrinkle removal, and urgent skin condition improvement, with varying recovery periods influencing consumer choices [3]. - Popular treatments have shifted from longer recovery options like Thermage and Ultherapy to shorter recovery options such as hyaluronic acid injections and photorejuvenation [3]. Group 2: Company Initiatives - Meituan has launched a "Beautiful New Year" campaign, offering a 3000 yuan medical beauty voucher package and a beauty calendar to help users select appropriate treatments based on recovery times [3]. - During the Spring Festival, at least 30% of medical beauty institutions on the Meituan platform will remain open, which is a 5% increase compared to the previous year, providing convenience for users seeking urgent skin treatments [3]. - The company promotes the "Safe Beauty" initiative to ensure compliance and safety in the industry, aiming to verify over 12 million treatment instances by the end of 2025 across 2500 institutions in 140 cities [4].